Related Experiment Video
Updated: Jun 14, 2026
03:43
Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
Published on: August 22, 2025
Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomas
Maider López De Jesús1, Cristina Hostalot, Jesús M Garibi
1Department of Pharmacology, University of the Basque Country, Leioa, Bizkaia, Spain.
Neurochemistry International
|March 24, 2010
Summary
Cannabinoid receptors CB(1) and CB(2) show altered expression in human gliomas. CB(1) levels decrease while CB(2) levels increase, suggesting potential therapeutic targets for brain tumors.
Area of Science:
- Neuroscience
- Oncology
- Pharmacology
Background:
- Gliomas are aggressive primary brain tumors with limited treatment options.
- Cannabinoids show potential in cancer therapy by inducing apoptosis and inhibiting angiogenesis.
- Cannabinoid effects are mediated through CB(1) and CB(2) receptors.
Purpose of the Study:
- To investigate the protein expression of CB(1) and CB(2) receptors in human glial tumors.
- To assess the functionality of cannabinoid receptors in glioblastomas.
Main Methods:
- Western blot analysis of CB(1) and CB(2) receptor protein expression in tumor tissues and control brain samples.
- Functional assessment using WIN 55,212-2 stimulated [(35)S]GTPgammaS binding assays in glioblastoma membranes.
Main Results:
- CB(1) receptor expression was significantly reduced in glioblastoma multiforme compared to normal brain tissue.
- CB(2) receptor expression was significantly elevated in glioblastoma multiforme and astrocytoma tissues.
- Cannabinoid receptor functionality, measured by GTPgammaS binding, was reduced in glioblastomas.
Conclusions:
- Human gliomas exhibit opposing changes in CB(1) and CB(2) receptor protein expression.
- Altered cannabinoid receptor expression and function in gliomas warrant further investigation for therapeutic strategies.
Related Concept Videos
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
01:15Receptor Downregulation in MVBs
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...